证券记录 · 已归档季度
NTRA
Natera, Inc. · Healthcare · Medical - Diagnostics & Research
18被追踪持有人
0Δ持有人
26.97M持有股份
$4.27B报告持仓市值
+0新建仓位
−0清仓
动量输入（同类管理人）： 持有人广度 0.0% · 股份流向 +10.5% · 净新建仓位 0.0% · 公式
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q4 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 6 | 0 | 535.21K | $217.82M | n/a | n/a |
| Q2 2026 | 162 | 0 | 104.13M | $28.25B | +5 | −4 |
| Q1 2026 | 164 | +3 | 98.65M | $19.54B | +6 | −4 |
| Q4 2025 | 160 | 0 | 102.31M | $23.44B | +1 | n/a |
| Q3 2025 | 23 | +1 | 81.70M | $13.15B | +1 | −1 |
| Q2 2025 | 20 | -1 | 57.32M | $9.68B | n/a | −1 |
| Q1 2025 | 18 | 0 | 31.15M | $4.40B | n/a | n/a |
| Q4 2024 | 18 | 0 | 26.97M | $4.27B | n/a | n/a |
| Q3 2024 | 17 | -1 | 21.42M | $2.72B | n/a | −1 |
| Q2 2024 | 18 | n/a | 16.29M | $1.76B | n/a | n/a |
持有人 · Q4 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 6.74M | +134.9% | $1.07B | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 2 | Duquesne Family Office ✦ | 3.57M | 0.0% | $564.63M | 15.9% | Held | 3 | SEC ↗ |
| 3 | Wellington Management ✦ | 3.24M | +15.7% | $512.90M | 0.1% | ▲ Add | 3 | SEC ↗ ×4 |
| 4 | State Street Global Advisors ✦ (被动) | 2.99M | n/a | $473.47M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (被动) | 2.23M | +6.8% | $355.81M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 6 | Citadel Advisors ✦ | 1.43M | -37.1% | $226.52M | 0.2% | ▼ Trim | 3 | SEC ↗ ×2 |
| 7 | Norges Bank ✦ (被动) | 1.42M | +3.0% | $224.04M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 945.51K | +21.8% | $149.67M | 0.2% | ▲ Add | 3 | SEC ↗ ×4 |
| 9 | ARK Investment Management ✦ | 887.71K | +29.1% | $140.52M | 1.2% | ▲ Add | 3 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 806.33K | -22.2% | $127.64M | 0.1% | ▼ Trim | 3 | SEC ↗ ×2 |
| 11 | Marshall Wace ✦ | 434.44K | -3.7% | $68.77M | 0.1% | ▼ Trim | 3 | SEC ↗ ×2 |
| 12 | Millennium Management ✦ | 396.84K | -72.0% | $62.82M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 13 | Capital World Investors ✦ | 396.42K | 0.0% | $62.75M | 0.0% | Held | 3 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 394.00K | -13.6% | $62.37M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 374.37K | -3.7% | $59.26M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 16 | Point72 Asset Management ✦ | 305.24K | -56.2% | $48.32M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 17 | Arrowstreet Capital ✦ | 296.37K | +874.1% | $46.92M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 109.50K | +9.9% | $17.33M | 0.2% | ▲ Add | 3 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 755 持有人, 120.14M 股份, $20.15B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Oct 21
Sheena Jonathan
Director · 627 股 · $257,003
Oct 21
Sheena Jonathan
Director · 605 股 · $248,847
Oct 21
Sheena Jonathan
Director · 962 股 · $392,745
Oct 21
Sheena Jonathan
Director · 125 股 · $51,631
Oct 21
Sheena Jonathan
Director · 211 股 · $86,974
Oct 21
Sheena Jonathan
Director · 255 股 · $105,995
Oct 21
Sheena Jonathan
Director · 165 股 · $68,751
Oct 21
Sheena Jonathan
Director · 200 股 · $81,300
Oct 16
Sheena Jonathan
Director · 80 股 · $32,484
Oct 16
Sheena Jonathan
Director · 50 股 · $20,258
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 14
SC 13G/A: PRICE T ROWE ASSOCIATES INC /MD/
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q4 2024 ·
方法论 ·
通过API获取此数据